Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.
about
Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cellsProtein kinases and phosphatases in the control of cell fateThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayActive monitoring of formaldehyde diffusion into histological tissues with digital acoustic interferometry.Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cellsSphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerProteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer.Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancerComparison of Akt/mTOR signaling in primary breast tumors and matched distant metastasesInositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells.Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinomaImpact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumorsCaffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells.A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.Clinical application for the preservation of phospho-proteins through in-situ tissue stabilizationPredictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence.Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expressionReceptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer.Cyclic phosphatidic acid stimulates cAMP production and inhibits growth in human colon cancer cells.Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cellsCastration-resistant prostate cancer: new science and therapeutic prospects.Androgen receptor signaling in prostate cancer development and progression.Development of a peptide-drug conjugate for prostate cancer therapy.Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancerImmunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors.Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesExpression of phosphorylated Akt/mTOR and clinical significance in human ameloblastoma.AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradationThe CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptorAbrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt
P2860
Q24293578-2A70A215-6B6F-4D60-84E8-F61B7AE3EB76Q24604987-A04F155E-A247-4874-9625-E5D5233824B4Q28076745-D69E62DE-D446-4C4A-ACC7-FE33463660FCQ28382812-921861BA-06C7-4E2D-8FA8-79720FDE0345Q30363844-E06CD35C-F6CC-4E5B-B9F5-A7FDB7A41943Q30654792-A40DC9E4-7D0E-4C72-A6DC-91F211D0DD24Q30940949-D3B11143-5A41-4183-9FE2-D018E32F89D9Q33284848-30BD55B8-1BD8-4D94-8BE2-DB2E57001419Q33443571-4F2C6B44-DA76-423F-82CE-FC1011C9DEC6Q33450135-51F0162D-57D6-464E-B258-1541CAEA93F8Q33499383-7D6E5328-0232-4062-8BA9-ACB09D095B9DQ33640816-69E00FC3-6F46-41A5-9C77-3F26F94BB066Q33644080-4656C02C-3AB4-4540-BC88-9C88C8BAD3C9Q34074062-1989CD69-2CFE-4882-ACC0-E088D897A6FFQ34075588-9ECE5504-4241-4720-BA16-45E292C81CA7Q34141720-B13FEC5F-5C66-41AA-94F8-48783146973AQ34162761-B46DB0DB-E012-4FA9-A4EF-1BCC82B37AF7Q34168896-977FFE86-F40C-4DFC-BA58-1B7C028F0909Q34196216-EE73127E-EF9D-4290-9FBA-797AC9C675DBQ34289164-6BAD78D0-ADE4-4429-98DC-308485CA2AE3Q34345248-4F71F13E-1C24-42EC-BC3A-3B00EB16D951Q34397827-7111B78A-28D9-4F0B-A34F-CDAFD49F11AAQ34427649-8DD4B4AB-4301-4EE8-A9CD-6EC07A001636Q34469245-E2C05099-9E92-437B-AF7D-7759F003A2ABQ34525572-B20FAE2E-6B76-4BBB-AF21-C0C7798E7336Q34766747-DDA03643-0EBC-475C-9AE5-479E8538D15BQ35055216-884CA45C-15F5-42D1-8E8D-0FD55D709BF1Q35070404-F21E8EAD-DA5C-4DD4-B4AC-2AAB19D637C2Q35076264-B529A300-C01D-4125-93AA-50C79B7BA57AQ35183663-990A02A6-ECDE-4756-8BE2-ECA84F952E31Q35184864-DDFCF17D-F906-4DDB-9166-3AF113D8B6C4Q35611347-F8D45255-699A-4C89-8540-A6B0F216A482Q35636781-0B961C7B-8F1C-460D-8D8E-147C8D15B971Q35740051-8F082964-376F-4554-8531-4DC9DB6B5C4DQ35749794-102D1BA2-2F90-47B6-B82B-FA787A35B428Q35791936-7BE70971-0189-425A-AA85-BB9D56109DCCQ35835242-647925F6-6C17-4544-B5EB-99D97159A4C5Q35838409-847AEC8B-1795-474A-B46F-2EB14D7D44B7Q35861043-F2CC437C-E125-42DD-94E5-F628463B1E15Q35945055-C736FE29-F822-4031-A60A-6756D7FB7181
P2860
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Phosphorylation of Akt (Ser473 ...... al outcome in prostate cancer.
@en
Phosphorylation of Akt
@nl
type
label
Phosphorylation of Akt (Ser473 ...... al outcome in prostate cancer.
@en
Phosphorylation of Akt
@nl
prefLabel
Phosphorylation of Akt (Ser473 ...... al outcome in prostate cancer.
@en
Phosphorylation of Akt
@nl
P2093
P1433
P1476
Phosphorylation of Akt (Ser473 ...... al outcome in prostate cancer.
@en
P2093
Dean A Troyer
Jeffrey I Kreisberg
Paramita M Ghosh
Roble G Bedolla
Shazli N Malik
Suzanne Kreisberg
Thomas J Prihoda
P304
P356
10.1158/0008-5472.CAN-04-0272
P407
P577
2004-08-01T00:00:00Z